Novartis Financial Results 2002 - GERMAN VIRTUAL PRESS KIT

January 23, 2003 06:00 ET | Source: Novartis Pharma AG Novartis Pharma AG

Part 1 - Media Release
http://hugin.info/134323/R/1011905/157554.pdf

Part 2 - Conference Program
http://hugin.info/134323/R/1011906/157555.pdf

Part 3 - Speakers Presentations

3.1 Daniel Vasella
http://hugin.info/134323/R/1011907/157556.pdf
http://hugin.info/134323/R/1011910/157557.pdf

3.2 Raymund Breu
http://hugin.info/134323/R/1011911/157558.pdf

3.3 Thomas Ebeling
http://hugin.info/134323/R/1011915/157561.pdf

3.4 Paul Choffat
http://hugin.info/134323/R/1011917/157562.pdf

3.5 David Epstein
http://hugin.info/134323/R/1011918/157565.pdf

Part 4 - Lebensläufe
http://hugin.info/134323/R/1011919/157566.pdf

Part 5 - Corporate Organizational Structure
http://hugin.info/134323/R/1011920/157567.pdf

Recommended Reading

April 24, 2026 01:15 ET | Source: Novartis Pharma AG

Novartis malaria treatment Coartem® Baby receives WHO prequalification, paving way for greater access for newborns and young infants

Coartem® (artemether-lumefantrine) Baby is the first and only malaria treatment for newborns and young infants, closing long-standing treatment gap WHO prequalification key milestone for donor-funded...
Read More
April 24, 2026 01:15 ET | Source: Novartis Pharma AG

Novartis malaria treatment Coartem® Baby receives WHO prequalification, paving way for greater access for newborns and young infants

Coartem® (artemether-lumefantrine) Baby is the first and only malaria treatment for newborns and young infants, closing long-standing treatment gap WHO prequalification key milestone for donor-funded...
Read More